|
|
|
Fortress Biotech Inc | 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP)
Prospectus excerpt: We are offering 1,000,000 shares of our 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock, which we refer to as the Series A Preferred Stock. Full Prospectus PDF », Secondary Prospectus PDF », FBIO Page »
Series: | A | Redeemable?: | Yes | Call Date: | 12/15/2022 (Now Trading Post Call Date) | Perpetual?: | Yes | Cumulative?: | Yes | Shares Offered: | 1,000,000 | Overallotment: | 150,000 | Liquidation Preference: | $25.00 | Recent Market Price: | $16.08 | Discount to Liquidation Preference: (More Preferreds Trading at a Discount ») | $-8.92 (-35.68%) | Annualized Dividend: | 2.343756 | Recent Ex-Date: | 4/12/2024 | Current Yield: | 14.58% | Original Coupon: | 9.375% | Pay Period: | Quarterly | Pay Dates: | 31-Mar, 30-Jun, 30-Sep, 31-Dec | CDx3 Compliance Rating: |
Learn FBIOP's Rating
|
|
Fortress Biotech is a biopharmaceutical company focused on acquiring, developing and commercializing pharmaceutical and biotechnology products and product candidates. Through its partner company, Co. markets dermatology products including Qbrexza®, which is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane® (isotretinoin) capsule, which is an oral capsule for the treatment of severe recalcitrant nodular acne; Ximino® (minocycline hydrochloride), which is an oral minocycline drug for the treatment of moderate to severe acne; as well as Targadox® (doxycycline hyclate), which is an oral doxycycline drug for adjunctive therapy for severe acne. Preferred: FBIOP Open the FBIO Information Page »
|
|
|
|
|